More Videos
SPECIAL REPORT
MOST SHARED
- Obama Sees Strains Unless US, China Balance Growth
- European Commission Objects to Sun Micro-Oracle Deal
- Can Apple Top Microsoft as Most Valuable Tech Firm?
- Mad Mail: Buy the Berkshire Hathaway Split?
- Cramer: 5 Stocks to Play the Next Bull Run
- JPMorgan Lifts Salary Freeze Amid Recovery
- Peak Oil Closer Than IEA Forecasts Show: Report
- GM CEO Starts Opel Charm Tour in Germany
- Yankees Team Signed Ball Selling For $3,500
- Pociask: In The Electronics War Does The Consumer Really Win?
- Why are Options Bullish on This Smartphone Maker?
- Is 10% Unemployment Good for Stocks?
- Moon Hopes To Complete Amazing Story
- Why Google is Paying $750 Million for Ad Mob
- Warren Buffett to Sell Stakes In Union Pacific & Norfolk Southern
- Nov. 9: Unusual Volume Leaders
- The Battered Businesses Behind Housing
- New Lows for Stocks Next Year: Equities Bear
- Small Business Sentiment Grows, But Fear Remains
- Peak Oil Closer Than IEA Forecasts Show: Report
- Yahoo Is in Expanding Mode, Hiring: CEO
- Tyco International Profit Falls Less Than Expected
- Justices Poke Fun at Patents for the Abstract
- UK Most at Risk of Losing Top Credit Rating: Fitch
- GM CEO Starts Charm Tour at Opel in Germany
- Vodafone Extends Cost-Cutting Scheme, Hits Targets
RSS FEED
Pharma's Market
Text Size 
On the Pfizer [PFE
Loading...
()
] earnings conference call this morning Chairman and CEO Jeff Kindler kicked things off by calling this a "time of great uncertainty in the world economy and capital markets and significant challenges in our industry."
As a Pfizer PR person pointed out in an email following my earnings story on "Squawk on the Street" this morning, worldwide Viagra sales in the second quarter were up 21 percent versus the same period last year, U.S. Viagra revenue was up a whopping 41 percent and international sales of the little blue pill rose nine percent. But I like to look behind the numbers, oftentimes much to the consternation of the above-mentioned PR person and his/her colleagues at PFE and at other drug companies.
And I think I found an interesting trend, if you can call it that. I went back through Pfizer's quarterly earnings reports over the past year. In the second quarter of 2007 U.S. Viagra sales were $142 million. They jumped to $208 million in Q3-'07, remained flat in Q4, and then shot up again in the first quarter of this year to $220 million. But in the second quarter--and I'm trying so hard to avoid obvious puns and plays on words--U.S. Viagra revenue fell to $199 million. Which brings me back to Kindler's opening statement about the economy.
I wonder if the weak American economy is causing men to cut out Viagra from their budgets. Or maybe more of them are cutting their pills in half. I know that urologists and the companies that make the erectile dysfunction drugs--PFE, Eli Lilly [LLY
Loading...
()
], GlaxoSmithKline [GSK
Loading...
()
], Schering-Plough [SGP
Loading...
()
] and Bayer [BAY
Loading...
()
] --are quick to say that impotence can be a sign of much more serious health problems and that the drugs shouldn't be viewed as lifestyle or recreational products, but that's how most people I know think of them. At drugstore.com 30 25mg pills cost nearly 400 bucks and that's supposedly with a 20 percent discount!
We'll find out if I'm onto something, perhaps, when LLY reports its earnings tomorrow morning and whether sales of Cialis are also down or maybe it's simply stealing market share from Viagra.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes